BPC 157 accelerated healing of transected rat Achilles tendon and stimulated tenocyte growth in vitro, supporting tendon-healing effects.
BPC-157
Body Protection Compound for accelerated tissue healing and repair

WADA BANNED - Prohibited in competitive sports as healing peptide
Overview
Last reviewed: 2026-08-18
Identity & Aliases
Also known as
Status: Investigational - Not approved for human use
Full composition (formula, molecular weight, sequence) in Quick Facts →
Research Areas
Available Evidence
No FDA approval and no large randomized controlled trials in humans were identified; published human evidence is essentially absent, with use limited to unregulated/off-label settings.
Extensive rat studies (mainly from the Zagreb group) show BPC 157 accelerates healing of transected Achilles tendon, improves tendon-to-bone healing at the myotendinous junction, protects gastrointestinal mucosa (Robert's cytoprotection paradigm), and modulates nitric oxide pathways.
In vitro studies report stimulation of tendon cell (tenocyte) growth and pro-angiogenic effects.
Claims of systemic 'whole-body healing', athletic recovery benefits and specific human dosing protocols are not supported by published clinical trials.
Key Studies & Findings
BPC 157 promoted healing of disabled rat myotendinous junctions after injury.
Review of BPC 157 in striated, smooth and heart muscle summarizes tissue-protective and healing effects across rat muscle injury models.
Review positions BPC 157 within Robert's gastric cytoprotection/organoprotection and stress-coping framework, summarizing gastrointestinal protection data.
Benefits & Effects
Gastrointestinal Protection: Anti-ulcer activity throughout GI tract, heals anastomoses
Wound Healing: Promotes skin, tendon, ligament, and GI tract healing via VEGF/angiogenesis pathways
Tendon/Ligament Repair: FAK-paxillin pathway activation; accelerates Achilles tendon healing
Side Effects & Safety
110 μg for a 150lb person
145 μg for a 200lb person
180 μg for a 250lb person
Mild side effect
Onset: During dosing
Management: Self-resolving after discontinuation
Dose-dependent
Limitations & Open Questions
Pharmacology
Reported Research Dosing
Reported values from research literature and community protocols. Educational reference only — not a dosing recommendation or medical advice.
200-500 mcg Daily
Research Protocols
Tendon/Joint healing
- Dose
- 250-500mcg
- Frequency
- 1-2x daily
- Route
- SubQ near injury
Serious injury
- Dose
- 500-1000mcg
- Frequency
- 2x daily
- Route
- SubQ near injury
General healing
- Dose
- 250-500mcg
- Frequency
- 1-2x daily
- Route
- SubQ or IM
Maintenance
- Dose
- 250mcg
- Frequency
- 1x daily
- Route
- SubQ
Research protocols are for educational purposes only. Always consult qualified medical professionals.
Frequently Asked Questions
Is BPC-157 FDA-approved?
No. It is not an approved drug anywhere; human use is off-label/research and largely unregulated.
Does BPC-157 work for tendon injuries?
Animal studies show accelerated tendon healing in rats, but human clinical confirmation is lacking.
Research Citations
Gwyer D, Wragg NM, Wilson SL (2019)
+ 45 more citations
Related Resources
Quick Facts
Formula
C62H98N16O22
Molecular Weight
1419.53
Sequence
GEPPPGKPADDAGLV
Mechanism
Promotes angiogenesis and tissue healing
Safety Information
No human clinical trials completed. Research compound only - not for human consumption.
Citations
50Gwyer D, Wragg NM, Wilson SL (2019)
+ 45 more citations